Immuron Limited

IMC

AU000000IMC7

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
0.105 ^AUD	0.00%		+5.00%	+36.36%

Apr. 10	Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	CI
Apr. 10	Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	MT

Immuron Presentation Australian Biologics Festival 2024

February 21, 2024 at 06:02 am EST

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21^st February in Melbourne, Australia.

A copy of the presentation slide deck is available on the Company’s website.

https://www.immuron.com.au/corporate-presentations/

Authorised for release by the Board of Immuron Limited.

COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com

Latest news about Immuron Limited

Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	Apr. 10	CI
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	Apr. 09	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Mar. 07	MT
Sector Update: Health Care	Mar. 07	MT
Top Midday Gainers	Mar. 07	MT
Top Premarket Gainers	Mar. 07	MT
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials	Mar. 07	MT
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	Mar. 07	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Immuron Limited Reports Unaudited Net Sales Results for the Year to Date Ended January 2024	Feb. 13	CI
Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January	Feb. 12	MT
Immuron Limited Reports Sales Results for First Half 2024	Jan. 16	CI
Immuron Posts Record Travelan Sales in Fiscal H1	Jan. 16	MT
Immuron Limited Clinical Trials Update	Dec. 22	CI
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	Dec. 04	CI
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	23-10-18	CI
Immuron Limited Reports Sales Results for the First Quarter of 2024	23-10-11	CI
Immuron Reports Big Jump in Fiscal Q1 Travelan Sales	23-10-11	MT
Immuron Sees Nearly 8000% Boost in August Sales of Gastrointestinal Drug	23-09-14	MT
Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Immuron Limited Receives TGA GMP Clearance	23-08-09	CI
Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%	23-08-09	MT
Immuron Says First Patients Enrolled in Travelan Trial	23-07-25	MT
Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study	23-07-25	CI
Immuron Enrolls First Patients in Travelan Clinical Study	23-07-25	MT

Chart Immuron Limited

Duration

Period

More charts

Company Profile

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects in Australia, Israel and the United States. The Company's flagship commercial products consist of Travelan and Protectyn. Travelan is an over the counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. The Company has four clinical programs -Travelan (IMM-124E), CampETEC, IMM-529 and Travelan (consumer product).

Sector

Pharmaceuticals

Calendar

2024-04-29 - Travelan Phase 2 Trial Results Call - Phase 3

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
IMMURON LIMITED	+36.36%	15.61M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B